Renal cell carcinoma in a transplanted kidney: a retrospective evaluation.
Genetic study of renal cell carcinoma in kidney transplant
Kidney graft neoplasm
Laparoscopic resection of kidney graft tumor
Renal cell carcinoma of the kidney graft
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
23
04
2024
accepted:
15
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
Kidney transplantation is the optimal treatment modality for patients with end-stage chronic kidney disease. The long-term mortality of kidney recipients is 48-82% lower than that of patients on the waiting list. However, the risk of developing malignancies in these patients is twice as high as in the healthy population. Specifically, the incidence of renal cell carcinoma (RCC) in transplant recipients is 10-30 times higher than in non-transplanted patients. The reason for the increased risk is poorly understood, but is most likely related to continuous immunosuppressive therapy. The problem of kidney graft neoplasia has not been adequately addressed in the medical literature. To determine the incidence of renal cell carcinoma in transplanted kidneys, enhance the efficacy of its treatment, and study the etiology of RCC development. A retrospective analysis of RCC incidence in kidney grafts was conducted in 3,270 patients who underwent kidney transplantation between 2013 and 2023. We evaluated the effectiveness of surgical interventions for these complications. Patients with histologically confirmed RCC of the transplanted kidney underwent genetic study to determine the etiology of the neoplasm. The incidence of RCC in transplanted kidneys was found to be 0.95% (n = 31), 28 patients underwent laparoscopic resection of the renal transplant tumor, 2 patients were treated with radiofrequency ablation of the tumor. Transplantectomy was performed in 1 patient. Laparoscopic resection is an effective and safe method for the treatment of RCC in kidney transplants. Transplanted kidney cancer originates from the donor tissue. The clear cell variant of transplanted kidney cancer is a genetically determined disease.
Identifiants
pubmed: 39075385
doi: 10.1186/s12882-024-03673-0
pii: 10.1186/s12882-024-03673-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Subventions
Organisme : Moscow Healthcare Department
ID : 2412-66
Organisme : Moscow Healthcare Department
ID : 2412-66
Informations de copyright
© 2024. The Author(s).
Références
Gautier SV, Khomyakov SM. Organ donation and transplantation in the Russian Federation in 2020 13th Report from the Registry of the Russian Transplant Society. Russian J Transplantology Artif Organs. 2021;23(3):8–34. https://doi.org/10.15825/1995-1191-2021-3-8-34 .
doi: 10.15825/1995-1191-2021-3-8-34
Andrusev AM, Peregudova NG, Shinkarev MB, Tomilina NA. Kidney replacement therapy for end stage kidney disease in Russian Federation, 2016–2020. Russian National Kidney Replacement Therapy Registry Report of Russian Public Organization of Nephrologists Russian Dialysis Society. Nephrologу Dialуsis. 2022;24(4):2.
Van Loon E, Senev A, Lerut E, Coemans M, Callemeyn J, Van Keer JM, Daniëls L, Kuypers D, Sprangers B, Emonds MP, Naesens M. Assessing the Complex Causes of Kidney Allograft Loss. Transplantation. 2020;104(12):2557–2566. https://doi.org/10.1097/TP.0000000000003192 . PMID: 32091487.
Lai X, Zheng X, Mathew JM, Gallon L, Leventhal JR, Zhang ZJ. Tackling chronic kidney transplant rejection: challenges and promises. Front Immunol. 2021;12:661643. https://doi.org/10.3389/fimmu.2021.661643 . PMID: 34093552; PMCID: PMC8173220.
doi: 10.3389/fimmu.2021.661643
pubmed: 34093552
pmcid: 8173220
Griffith JJ, Amin KA, Waingankar N, Lerner SM, Delaney V, Ames SA, Badani K, Palese MA, Mehrazin R. Solid renal masses in transplanted allograft kidneys: a closer look at the epidemiology and management. Am J Transpl. 2017;17(11):2775–81. https://doi.org/10.1111/ajt.14366 . Epub 2017 Jun 27. PMID: 28544435.
doi: 10.1111/ajt.14366
Tillou X, Guleryuz K, Collon S, Doerfler A. Renal cell carcinoma in functional renal graft: toward ablative treatments. Transpl Rev (Orlando). 2016;30(1):20–6. https://doi.org/10.1016/j.trre.2015.07.001 . Epub 2015 Aug 1. PMID: 26318289.
doi: 10.1016/j.trre.2015.07.001
Favi E, Raison N, Ambrogi F, Delbue S, Clementi MC, Lamperti L, Perego M, Bischeri M, Ferraresso M. Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World J Clin Cases. 2019;7(17):2487–504. https://doi.org/10.12998/wjcc.v7.i17.2487 . PMID: 31559284; PMCID: PMC6745334.
doi: 10.12998/wjcc.v7.i17.2487
pubmed: 31559284
pmcid: 6745334
Crespo E, Fernandez L, Lúcia M, Melilli E, Lauzurica R, Penin RM, Quer A, Luque S, Quero M, Manonelles A, Torras J, Cruzado JM, Cañas L, Grinyó JM, Bestard O. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients. Transplantation. 2017;101(9):2102–2110. https://doi.org/10.1097/TP.0000000000001759 . PMID: 28403126.
Maluccio M, Sharma V, Lagman M, Vyas S, Yang H, Li B, Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003;76(3):597–602. https://doi.org/10.1097/01.TP.0000081399.75231.3B . PMID: 12923450.
Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 2016;29(1):104–16. PMID: 26766592; PMCID: PMC4809063.
doi: 10.1016/j.ccell.2015.12.004
pubmed: 26766592
pmcid: 4809063